The 11/18 show is the first installation in a new series that highlights emerging voices with accessible pay-what-you-can ...
Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback